Jeremy Bender - 15 Nov 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role: Chief Executive Officer, Director
Signature: /s/ Charles N. York II, Attorney-in-Fact
Issuer symbol: DAWN
Transactions as of: 15 Nov 2022
Transactions value $: $-32,469
Form type: 4
Filing time: 17 Nov 2022, 16:33:43 UTC
Previous filing: 03 Nov 2022
Next filing: 22 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DAWN	Common Stock	Options Exercise		+3,562	+0.29%		1,218,937	15 Nov 2022	Direct	F1
transaction	DAWN	Common Stock	Sale	$-32,469	-1,513	-0.12%	$21.46	1,217,424	16 Nov 2022	Direct	F2
holding	DAWN	Common Stock						281,574	15 Nov 2022	See Footnote	F3
holding	DAWN	Common Stock						281,574	15 Nov 2022	See Footnote	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DAWN	Restricted Stock Units	Options Exercise	$0	-3,562	-7.69%	$0.000000	42,752	15 Nov 2022	Common Stock	3,562		Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2	The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
F3	Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
F4	Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.
F5	The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date.